Kilitch Drugs (India) Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Mukund Mehta
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 32.6yrs |
| CEO ownership | 7.1% |
| Management average tenure | 2.6yrs |
| Board average tenure | 7.3yrs |
Recent management updates
Recent updates
Kilitch Drugs (India) Limited (NSE:KILITCH) Not Flying Under The Radar
Jul 23
Here's Why Kilitch Drugs (India) (NSE:KILITCH) Can Manage Its Debt Responsibly
Mar 05Kilitch Drugs (India) Limited (NSE:KILITCH) Looks Just Right With A 26% Price Jump
Feb 02We Ran A Stock Scan For Earnings Growth And Kilitch Drugs (India) (NSE:KILITCH) Passed With Ease
Jan 30Investors Shouldn't Be Too Comfortable With Kilitch Drugs (India)'s (NSE:KILITCH) Earnings
Nov 17Shareholders Would Not Be Objecting To Kilitch Drugs (India) Limited's (NSE:KILITCH) CEO Compensation And Here's Why
Sep 23These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well
Sep 08Here's Why Kilitch Drugs (India) (NSE:KILITCH) Has Caught The Eye Of Investors
May 05Kilitch Drugs (India) (NSE:KILITCH) Could Easily Take On More Debt
Jul 06Here's Why I Think Kilitch Drugs (India) (NSE:KILITCH) Might Deserve Your Attention Today
Apr 08These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well
Dec 17Is Kilitch Drugs (India) (NSE:KILITCH) Using Too Much Debt?
Mar 21Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Feb 13Is Kilitch Drugs (India) (NSE:KILITCH) Weighed On By Its Debt Load?
Dec 03
Does Kilitch Drugs (India) Limited (NSE:KILITCH) Have A Place In Your Dividend Stock Portfolio?
Aug 20Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Jul 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹165m |
| Jun 30 2024 | n/a | n/a | ₹126m |
| Mar 31 2024 | n/a | n/a | ₹146m |
| Dec 31 2023 | n/a | n/a | ₹146m |
| Sep 30 2023 | n/a | n/a | ₹140m |
| Jun 30 2023 | n/a | n/a | ₹117m |
| Mar 31 2023 | ₹6m | ₹6m | ₹104m |
| Dec 31 2022 | n/a | n/a | ₹98m |
| Sep 30 2022 | n/a | n/a | ₹85m |
| Jun 30 2022 | n/a | n/a | ₹83m |
| Mar 31 2022 | ₹6m | ₹6m | ₹74m |
| Dec 31 2021 | n/a | n/a | ₹52m |
| Sep 30 2021 | n/a | n/a | ₹63m |
| Jun 30 2021 | n/a | n/a | ₹62m |
| Mar 31 2021 | ₹6m | n/a | ₹37m |
| Dec 31 2020 | n/a | n/a | ₹17m |
| Sep 30 2020 | n/a | n/a | ₹4m |
| Jun 30 2020 | n/a | n/a | -₹3m |
| Mar 31 2020 | ₹6m | n/a | ₹8m |
Compensation vs Market: Insufficient data to establish whether Mukund's total compensation is reasonable compared to companies of similar size in the Indian market.
Compensation vs Earnings: Mukund's compensation has been consistent with company performance over the past year.
CEO
Mukund Mehta (71 yo)
32.6yrs
Tenure
₹6,000,000
Compensation
Mr. Mukund Prataprai Mehta, B.Com, LL B., serves as the Chairman and Managing Director at Kilitch Drugs (India) Limited and has been its Executive Director since May 12, 1992. Mr. Mehta served as the Compl...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & MD | no data | ₹6.00m | 7.09% ₹ 368.7m | |
| Managing Director | less than a year | ₹2.40m | 5.23% ₹ 271.9m | |
| Whole-time Director | no data | ₹8.40m | 15.69% ₹ 815.6m | |
| Chief Financial Officer | 3.8yrs | ₹1.50m | no data | |
| VP-Marketing & Operation | no data | no data | no data | |
| General Manager - Administration | no data | no data | no data | |
| Company Secretary & Compliance Officer | 2.6yrs | no data | no data |
2.6yrs
Average Tenure
48yo
Average Age
Experienced Management: KILITCH's management team is considered experienced (2.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & MD | 32.6yrs | ₹6.00m | 7.09% ₹ 368.7m | |
| Managing Director | 10.1yrs | ₹2.40m | 5.23% ₹ 271.9m | |
| Whole-time Director | 7.3yrs | ₹8.40m | 15.69% ₹ 815.6m | |
| Independent & Non Executive Director | 16.5yrs | ₹25.00k | no data | |
| Non-Executive Independent Director | 6.8yrs | ₹30.00k | no data | |
| Independent Non-Executive Director | 6.5yrs | ₹5.00k | no data | |
| Non- Executive Independent Director | less than a year | no data | no data |
7.3yrs
Average Tenure
65yo
Average Age
Experienced Board: KILITCH's board of directors are considered experienced (7.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/28 04:14 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kilitch Drugs (India) Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|